Billy Amzal

SVP, Decision and Real-World Data Analytics

About Billy Amzal

Billy Amzal is Senior Vice President, Decision and Real-World Data analytics in Analytica Laser, Certara’s Evidence and Access Group, and serves as a senior management capacity. In this role, he oversees scientific developments and implementation within all consultancy and analytics projects. Billy is an analytical, highly numerate, results-oriented leader with proven success in developing best-in-class quantitative tools for decision making, and managing high performance, multi-disciplinary teams.

Billy has spent over 15 years developing advanced quantitative tools to support decision making from early clinical development to late-phase real-world and public health impact evaluations. Billy has developed more than a hundred advanced patient-level models and is an expert in study simulations, optimal design, Bayesian models and algorithms, quantitative decision analysis and real-world analytics. He is pioneering the development of an efficacy-to-effectiveness bridging study concept for optimal real-world generation. Billy also plays an active role in a number of methodological guidelines developments and international scientific initiatives, e.g. within DIA and ISPOR and EMA/IMI projects such as PROTECT and GETREAL.

Billy is an active member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), the International Society for Pharmaco-Epidemiology (ISPE) and the International Society for Bayesian Analysis (ISBA). He acts as a modelling expert in various health agencies such as the European Food Safety Authority (EFSA), the French National Agency of Health and Safety (ANSES) and the World Health Organization (WHO). Billy teaches pharmacoeconomics at Paris University.

Prior to joining Analytica Laser Billy headed an epidemiological data research center on HIV in Thailand from the Harvard School of Public Health. Billy also led the development of assessment methodology at EFSA and model-based drug development at Novartis Pharma.

Billy graduated in mathematical engineering from Ecole Polytechnique in France. He holds an MSc in probability and statistics from Université Paris 6, a Master of Public Health Administration from AgroParisTech and a PhD in Decision Mathematics from Paris-Dauphine, which was awarded by the International Society for Bayesian Analysis and by the International Biometrics Society.